Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005.
暂无分享,去创建一个
[1] S. Dahlén,et al. Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. , 1997, Thorax.
[2] P. Sterk,et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. , 1995, The Journal of allergy and clinical immunology.
[3] W. Henderson. The Role of Leukotrienes in Inflammation , 1994, Annals of Internal Medicine.
[4] A. Williams,et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. , 1994, Thorax.
[5] C. Labat,et al. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. , 1994, The Journal of pharmacology and experimental therapeutics.
[6] B. Beckermann,et al. BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. , 1993, The Journal of pharmacology and experimental therapeutics.
[7] T. Haahtela,et al. Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.
[8] P. Sterk,et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. , 1993, The American review of respiratory disease.
[9] A. Hatzelmann,et al. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. , 1993, Biochemical pharmacology.
[10] D. Margolskee,et al. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. , 1992, The Journal of allergy and clinical immunology.
[11] C. Dollery,et al. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects , 1991, The Lancet.
[12] Paul H. Rubin,et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. , 1991, Thorax.
[13] P. O'Byrne,et al. Urinary leukotriene E4 levels during early and late asthmatic responses. , 1990, The Journal of allergy and clinical immunology.
[14] S. Wenzel,et al. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. , 1990, The American review of respiratory disease.
[15] C. Dollery,et al. URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITIS , 1989, The Lancet.
[16] J. Arm,et al. The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. , 1988, The Journal of allergy and clinical immunology.
[17] D. Cockcroft,et al. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.
[18] J. Drazen,et al. Leukotrienes and airway responses. , 1987, The American review of respiratory disease.
[19] E. R. Mcfadden,et al. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. , 1987, The American review of respiratory disease.
[20] P. O'Byrne,et al. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. , 1986, The New England journal of medicine.
[21] H. Sluiter,et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.
[22] N. Barnes,et al. Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. , 1984, Thorax.
[23] M. Wasserman,et al. Investigation of leukotriene involvement in the vasopermeability response associated with guinea pig tracheal anaphylaxis: comparison with cutaneous anaphylaxis. , 1983, European journal of pharmacology.
[24] H. G. Johnson,et al. Secretogogue responses of leukotriene C4, D4: comparison of potency in canine trachea in vivo. , 1983, Prostaglandins.
[25] J. Shelhamer,et al. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. , 2015, The American review of respiratory disease.
[26] N. Thomson,et al. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. , 1982, The Journal of allergy and clinical immunology.
[27] P. Paré,et al. Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro , 1981, Nature.
[28] Bengt Samuelsson,et al. Leukotrienes are potent constrictors of human bronchi , 1980, Nature.
[29] M. Hills,et al. The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.
[30] D. Cockcroft,et al. 154. Allergen-induced increase in nonallergic (nonspecific) bronchial reactivity; its relation to the late asthmatic response , 1978 .
[31] D. Cockcroft,et al. Allergen‐induced increase in non‐allergic bronchial reactivity , 1977, Clinical allergy.
[32] F. Hargreave,et al. Bronchial reactivity to inhaled histamine: a method and clinical survey , 1977, Clinical allergy.
[33] J. Morris,et al. Spirometric standards for healthy nonsmoking adults. , 2015, The American review of respiratory disease.